Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
25%
Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 31 (50.0%)
N/A1 (50.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completed

Community-based Sero-epidemiological Study of COVID-19

NCT05599555
completed

Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong

NCT04898946
completedphase_3

Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

NCT05188677
completednot_applicable

SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients

NCT05313074

Clinical Trials (4)

Showing 4 of 4 trials
NCT05599555

Community-based Sero-epidemiological Study of COVID-19

Completed
NCT04898946

Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong

Completed
NCT05188677Phase 3

Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

Completed
NCT05313074Not Applicable

SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4